Charles River Laboratories International (CRL) Long-Term Debt Repayments: 2009-2025
Historic Long-Term Debt Repayments for Charles River Laboratories International (CRL) over the last 16 years, with Sep 2025 value amounting to $253.8 million.
- Charles River Laboratories International's Long-Term Debt Repayments fell 23.01% to $253.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 19.51%. This contributed to the annual value of $1.5 billion for FY2024, which is 75.39% up from last year.
- As of Q3 2025, Charles River Laboratories International's Long-Term Debt Repayments stood at $253.8 million, which was down 65.63% from $738.3 million recorded in Q2 2025.
- In the past 5 years, Charles River Laboratories International's Long-Term Debt Repayments registered a high of $2.5 billion during Q2 2021, and its lowest value of $149.4 million during Q1 2025.
- In the last 3 years, Charles River Laboratories International's Long-Term Debt Repayments had a median value of $253.8 million in 2025 and averaged $317.0 million.
- Its Long-Term Debt Repayments has fluctuated over the past 5 years, first soared by 2,004.10% in 2021, then tumbled by 83.41% in 2023.
- Quarterly analysis of 5 years shows Charles River Laboratories International's Long-Term Debt Repayments stood at $1.1 billion in 2021, then slumped by 61.21% to $408.2 million in 2022, then decreased by 21.43% to $320.8 million in 2023, then plummeted by 44.89% to $176.8 million in 2024, then declined by 23.01% to $253.8 million in 2025.
- Its Long-Term Debt Repayments was $253.8 million in Q3 2025, compared to $738.3 million in Q2 2025 and $149.4 million in Q1 2025.